Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

LDCT Screening Cost-Effectiveness for Familial Lung Cancer Risk in Taiwan.

Created on 11 Nov 2026

Authors

Feng-Chi Hsieh, Chao-Hong Liu, Hon-Yi Shi

Published in

The American journal of managed care. Volume 32. Issue 10. Pages e364-e371. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Most economic evaluations of low-dose CT (LDCT) screening focus on heavy smokers, with limited evidence for individuals with a family history of lung cancer (LCFH). This study evaluated the cost-effectiveness of LDCT screening for individuals with LCFH using Taiwan epidemiologic data and cost data derived from the Taiwan National Health Insurance program.
A Markov model simulation evaluated the cost-effectiveness of LDCT screening vs nonscreening using 10,000 iterations in the probabilistic sensitivity analysis, a 1-year cycle, a 20-year time horizon, and a 3% annual discount rate.
The analysis adopted the perspective of the Taiwan health care payer and assumed annual LDCT screening with full adherence. The willingness-to-pay (WTP) threshold was set at $32,440, corresponding to Taiwan's 2024 gross domestic product per capita. We used incremental costs and quality-adjusted life years (QALYs) to calculate the incremental cost-utility ratio (ICUR). Deterministic and probabilistic sensitivity analyses were conducted to evaluate parameter uncertainty.
At the specified WTP threshold, LDCT screening yielded an ICUR of $23,786/QALYs, which was below the prespecified WTP threshold. In the simulated cohort, 158,375 LDCT examinations resulted in 609 lung cancer diagnoses over 20 years. Probabilistic sensitivity analysis demonstrated a 61.22% probability of cost-effectiveness. Results were most sensitive to lung cancer incidence in the nonscreening cohort, LDCT positivity rate, and positive predictive value.
LDCT screening for individuals with LCFH was cost-effective at the selected threshold under modeled assumptions. Targeted implementation in high-risk populations may enhance value-based resource allocation; however, real-world adherence, evolving treatment costs, and program scalability should be considered in coverage and reimbursement decisions.

PMID:
43007652
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement